The Ergomed CRO services provider model seems to involve discounting the clinical management costs for shares in the development rights of the new compound

Sounds like bit of an extreme and risky way of getting business to me

>>>

http://www.proactiveinvestors.co.uk/companies/news/124711/ergomed-s-hybrid-strategy-gives-it-plenty-of-ammo-124711.html